Cargando…
The impact of Medicare prescription drug coverage on the use of antidementia drugs
BACKGROUND: Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and caregivers, has been questioned. Little is known about whether the demand for cho...
Autores principales: | Fowler, Nicole R, Chen, Yi-Fan, Thurton, Christiana A, Men, Aiju, Rodriguez, Eric G, Donohue, Julie M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651712/ https://www.ncbi.nlm.nih.gov/pubmed/23621892 http://dx.doi.org/10.1186/1471-2318-13-37 |
Ejemplares similares
-
Prescription Drug Coverage and Spending for Medicare Beneficiaries
por: Poisal, John A., et al.
Publicado: (1999) -
MCBS Highlights: Prescription Drug Coverage Among Medicare Beneficiaries
por: Regan, Joseph F., et al.
Publicado: (2007) -
Antidementia drug use in Japan: Bridging the research‐to‐practice gap
por: Okumura, Yasuyuki, et al.
Publicado: (2018) -
Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
por: Shaw, Daniel L., et al.
Publicado: (2018) -
Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India
por: Prasad, Krishna, et al.
Publicado: (2009)